MetaVia Initiates Higher-Dose Phase 1 DA-1726 Study After 9% Weight-Loss Results
MetaVia has dosed the first patient in Part 3 of its Phase 1 DA-1726 trial, testing one-step titration to 48 mg and two-step titration to 64 mg in 40 obese adults. Prior cohorts achieved 9% weight loss at 48 mg with waist and glycemic gains; Part 3 data arrive in Q4 2026.
1. Part 3 Dose-Escalation Design
Part 3 includes two 16-week titration cohorts enrolling 40 obese adults randomized 4:1 active to placebo. Part 3A tests one-step titration with 16 mg for four weeks then 48 mg for 12 weeks; Part 3B uses a two-step regimen of 16 mg for four weeks, 32 mg for four weeks and 64 mg for eight weeks.
2. Early Phase Results
Earlier cohorts demonstrated approximately 9% mean weight loss at the 48 mg dose along with significant reductions in waist circumference, improved glycemic control and a favorable safety and tolerability profile, supporting higher-dose evaluation of DA-1726.
3. Next Milestones
MetaVia plans to report comprehensive safety, pharmacokinetics, pharmacodynamics and metabolic endpoint data in the fourth quarter of 2026, aiming to establish DA-1726’s differentiated efficacy and more streamlined dosing compared to existing obesity therapies.